Table 1.
Clinical and pathological characteristics of participants for TCC and Moffitt validation.
| TCGA | TCC | Moffitt | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Dead (n = 169) | Alive (n = 346) | p value | Dead (n = 141) | Alive (n = 157) | p value | Short‐term survivors (n = 72) | Long‐term survivors (n = 176) | p value | |
| Gender | 0.65 | 0.24 | 0.045 | ||||||
| Female | 63 (37%) | 122 (35%) | 49 (35%) | 60 (38%) | 16 (22%) | 62 (35%) | |||
| Male | 106 (63%) | 224 (65%) | 92 (65%) | 97 (62%) | 56 (78%) | 114 (65%) | |||
| Race | 0.04 | 0.139 | 0.008 | ||||||
| Black | 11 (7%) | 44 (13%) | 3 (2%) | 6 (4%) | 8 (11%) | 5 (3%) | |||
| White | 155 (92%) | 290 (85%) | 137 (97%) | 145 (92%) | 64(89%) | 171 (97%) | |||
| Other | 1 (1%) | 7 (2) | 1 (1%) | 6 (4%) | |||||
| SEER Stage | <0.0001 | <0.0001 | 0.004 | ||||||
| Localized | 53 (31%) | 254 (73%) | 46 (33%) | 126 (80%) | 38 (53%) | 120 (68%) | |||
| Reginal | 50 (30%) | 76 (22%) | 39 (28%) | 21 (13%) | 21 (29%) | 21 (12%) | |||
| Distant met | 66 (39%) | 16 (5%) | 53 (38%) | 10 (7%) | 13 (18%) | 35 (20%) | |||
| Unknown | 3 (2%) | 0 (0%) | |||||||
| Stage | <0.0001 | <0.0001 | <0.0001 | ||||||
| 1 | 40 (24%) | 212 (61%) | 33 (23%) | 105 (69%) | 5 (7%) | 110 (62%) | |||
| 2 | 12 (7%) | 42 (12%) | 14 (10%) | 14 (9%) | 9 (12%) | 13 (7%) | |||
| 3 | 49 (29%) | 74 (21%) | 32 (23%) | 25 (16%) | 40 (56%) | 31 (18%) | |||
| 4 | 67 (40%) | 16 (5%) | 55 (39%) | 10 (6%) | 18 (25%) | 22 (13%) | |||
| Unknown | 1 (1%) | 2 (1%) | 7 (5%) | 3 (2%) | |||||
| Vital Status | <0.0001 | <0.0001 | <0.0001 | ||||||
| Alive | 0 (0%) | 346 (100%) | 0 (0%) | 157 (100%) | 0 (0%) | 137 (78%) | |||
| Dead | 169 (100%) | 0 (0%) | 141 (100%) | 0 (0%) | 72 (100%) | 39 (22%) | |||